1. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. Issue 6 (11th June 2021) Authors: Zakharia, Yousef; McWilliams, Robert R; Rixe, Olivier; Drabick, Joseph; Shaheen, Montaser F; Grossmann, Kenneth F; Kolhe, Ravindra; Pacholczyk, Rafal; Sadek, Ramses; Tennant, Lucinda L; Smith, Christopher M; Kennedy, Eugene P; Link Jr, Charles J; Vahanian, Nicholas N; Yu, Jiayi; Shen, Steven S; B... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 6(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗